Poland· PL-100537676
Ojemda
A tovorafenib product containing tovorafenib, registered in Poland by Ipsen Pharma. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tovorafenib is registered in 9 of 19 countries.
Countries holding a registration under ATC L01EC04 (tovorafenib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Tovorafenib · ATC L01EC04
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Tovorafenib
- Manufacturer
- Ipsen Pharma
- Country
- Poland (PL)
- ATC code
- L01EC04
- ATC class
- Tovorafenib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin03582180004292
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tovorafenib in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOjemda 25 mg/mlIpsen Pharma
- SwitzerlandOjemda 25 mg/ml, Pulver zur Herstellung einer Suspension zum EinnehmenIPSEN Pharma Schweiz GmbH
- CzechiaOJEMDAIPSEN PHARMA S.A.S., Paříž
- FinlandOjemdaIpsen Pharma
- IcelandOjemdaIpsen Pharma
- NetherlandsOjemda 25 mg/ml poeder voor suspensie voor oraal gebruikIpsen Pharma
- SwedenOjemda 25 mg/ml Pulver till oral suspensionIpsen Pharma
- United StatesOJEMDADay One Biopharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ojemda
- Liechtenstein · Ojemda
- Norway · Ojemda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4c163122-44b8-457c-89eb-dea3b64d9c6d GET /v1/drugs/4c163122-44b8-457c-89eb-dea3b64d9c6d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania zawiesiny doustnej",
"source": "urpl",
"strength": "25 mg/ml",
"packaging": "Rpz ¦ EU/1/26/2025/004 ¦ 166900\n1 butelka 30 ml ¦ 1 strzykawka doustna + adapter butelki\n¦ UR/Z/4b/173/26 - 03582180004292",
"substance": "Tovorafenib 25 mg/ml",
"common_name": "Tovorafenib",
"pl_product_id": "100537676",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tovorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.